Caterina Mucherino

Caserta, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Effectiveness and Safety of Risankizumab in Crohn Disease After Failure of a First Line of Advanced Therapy: A Long-Term, Real-Life Study.

Effectiveness and Safety of Risankizumab in Crohn Disease After Failure of a First Line of Advanced Therapy: A Long-Term, Real-Life Study.

Journal: American journal of therapeutics

Published: July 23, 2026

Effectiveness and Safety of Risankizumab in Crohn Disease After Failure of a First Line of Advanced Therapy: A Long-Term, Real-Life Study.

Effectiveness and Safety of Risankizumab in Crohn Disease After Failure of a First Line of Advanced Therapy: A Long-Term, Real-Life Study.

Journal: American journal of therapeutics

Published: July 23, 2026

Comparative Effectiveness and Safety of Tofacitinib, Filgotinib, and Upadacitinib in Ulcerative Colitis: A Multicenter Real-World Cohort Study.

Comparative Effectiveness and Safety of Tofacitinib, Filgotinib, and Upadacitinib in Ulcerative Colitis: A Multicenter Real-World Cohort Study.

Journal: Advances in therapy

Published: February 11, 2026

Upadacitinib's Effectiveness and Safety as a Second- or Third-Line Therapy in Patients with Ulcerative Colitis: Data from a Real-World Study.

Upadacitinib's Effectiveness and Safety as a Second- or Third-Line Therapy in Patients with Ulcerative Colitis: Data from a Real-World Study.

Journal: Journal of clinical medicine

Published: August 27, 2025

Filgotinib effectiveness and safety as second or third-line therapy in patients with ulcerative colitis: data from a real-world study.

Filgotinib effectiveness and safety as second or third-line therapy in patients with ulcerative colitis: data from a real-world study.

Journal: Intestinal research

Published: April 29, 2025

Long-Term Effectiveness and Safety of Ustekinumab in Crohn's Disease: Results from a Large Real-Life Cohort Study.

Long-Term Effectiveness and Safety of Ustekinumab in Crohn's Disease: Results from a Large Real-Life Cohort Study.

Journal: Journal of clinical medicine

Published: September 23, 2024

Lower urinary tract symptoms in patients with inflammatory bowel diseases: A cross-sectional observational study.

Lower urinary tract symptoms in patients with inflammatory bowel diseases: A cross-sectional observational study.

Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

Published: July 21, 2023

Erectile and sexual dysfunction in male and female patients with celiac disease: A cross-sectional observational study.

Erectile and sexual dysfunction in male and female patients with celiac disease: A cross-sectional observational study.

Journal: Andrology

Published: February 25, 2022

Efficacy of ustekinumab in the treatment of patients with Crohn's disease with failure to previous conventional or biologic therapy: a prospective observational real-life study.

Efficacy of ustekinumab in the treatment of patients with Crohn's disease with failure to previous conventional or biologic therapy: a prospective observational real-life study.

Journal: Journal of physiology and pharmacology : an official journal of the Polish Physiological Society

Published: July 18, 2021

Non-bismuth and bismuth quadruple therapies based on previous clarithromycin exposure are as effective and safe in an area of high clarithromycin resistance: A real-life study.

Non-bismuth and bismuth quadruple therapies based on previous clarithromycin exposure are as effective and safe in an area of high clarithromycin resistance: A real-life study.

Journal: Helicobacter

Published: January 25, 2020

Showing 1-10 of 10

Last Updated: 09/26/2026